BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 18541119)

  • 1. Drug delivery to brain tumors.
    Blakeley J
    Curr Neurol Neurosci Rep; 2008 May; 8(3):235-41. PubMed ID: 18541119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer.
    Papademetriou IT; Porter T
    Ther Deliv; 2015; 6(8):989-1016. PubMed ID: 26488496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous.
    Drapeau A; Fortin D
    Curr Cancer Drug Targets; 2015; 15(9):752-68. PubMed ID: 26077730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic chemotherapy: advances in delivery, pharmacology, and testing.
    Ciordia R; Supko J; Gatineau M; Batchelor T
    Curr Oncol Rep; 2000 Sep; 2(5):445-53. PubMed ID: 11122877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for increasing drug delivery to the brain: focus on brain lymphoma.
    Siegal T; Zylber-Katz E
    Clin Pharmacokinet; 2002; 41(3):171-86. PubMed ID: 11929318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going.
    D'Amico RS; Khatri D; Reichman N; Patel NV; Wong T; Fralin SR; Li M; Ellis JA; Ortiz R; Langer DJ; Boockvar JA
    J Neurooncol; 2020 Apr; 147(2):261-278. PubMed ID: 32076934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier.
    Parrish KE; Sarkaria JN; Elmquist WF
    Clin Pharmacol Ther; 2015 Apr; 97(4):336-46. PubMed ID: 25669487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood-brain barrier disruption in the treatment of brain tumors.
    Blanchette M; Fortin D
    Methods Mol Biol; 2011; 686():447-63. PubMed ID: 21082387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in drug delivery to tumors of the central nervous system: an overview of pharmacological and surgical considerations.
    Serwer LP; James CD
    Adv Drug Deliv Rev; 2012 May; 64(7):590-7. PubMed ID: 22306489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing the Delivery of Antineoplastic Therapies to the Central Nervous System.
    Naidoo J; Panday H; Jackson S; Grossman SA
    Oncology (Williston Park); 2016 Nov; 30(11):953-62. PubMed ID: 27854097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug delivery systems for brain tumor therapy.
    Rautioa J; Chikhale PJ
    Curr Pharm Des; 2004; 10(12):1341-53. PubMed ID: 15134485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of permeability, doxorubicin delivery, and drug retention in a rat brain tumor model after ultrasound-induced blood-tumor barrier disruption.
    Park J; Aryal M; Vykhodtseva N; Zhang YZ; McDannold N
    J Control Release; 2017 Mar; 250():77-85. PubMed ID: 27742444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug delivery strategies to enhance the permeability of the blood-brain barrier for treatment of glioma.
    Zhang F; Xu CL; Liu CM
    Drug Des Devel Ther; 2015; 9():2089-100. PubMed ID: 25926719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming the blood-brain barrier for chemotherapy: limitations, challenges and rising problems.
    Wang Z; Sun H; Yakisich JS
    Anticancer Agents Med Chem; 2014; 14(8):1085-93. PubMed ID: 23092271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Delivery to Central Nervous System.
    Kunigelis KE; Vogelbaum MA
    Neurosurg Clin N Am; 2021 Apr; 32(2):291-303. PubMed ID: 33781509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of potential applications of MR-guided focused ultrasound for targeting brain tumor therapy.
    Lamsam L; Johnson E; Connolly ID; Wintermark M; Hayden Gephart M
    Neurosurg Focus; 2018 Feb; 44(2):E10. PubMed ID: 29385922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives on Dual Targeting Delivery Systems for Brain Tumors.
    Gao H
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):6-16. PubMed ID: 27270720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
    Wang D; Wang C; Wang L; Chen Y
    Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium.
    Doolittle ND; Abrey LE; Ferrari N; Hall WA; Laws ER; McLendon RE; Muldoon LL; Peereboom D; Peterson DR; Reynolds CP; Senter P; Neuwelt EA
    Clin Cancer Res; 2002 Jun; 8(6):1702-9. PubMed ID: 12060607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The blood-brain/tumor barriers: challenges and chances for malignant gliomas targeted drug delivery.
    Zhan C; Lu W
    Curr Pharm Biotechnol; 2012 Sep; 13(12):2380-7. PubMed ID: 23016643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.